BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 26634708)

  • 41. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma.
    Horn H; Ziepert M; Wartenberg M; Staiger AM; Barth TF; Bernd HW; Feller AC; Klapper W; Stuhlmann-Laeisz C; Hummel M; Stein H; Lenze D; Hartmann S; Hansmann ML; Möller P; Cogliatti S; Pfreundschuh M; Trümper L; Loeffler M; Glass B; Schmitz N; Ott G; Rosenwald A;
    Leukemia; 2015 Jul; 29(7):1564-70. PubMed ID: 25687653
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation.
    Sun H; Savage KJ; Karsan A; Slack GW; Gascoyne RD; Toze CL; Sehn LH; Abou Mourad Y; Barnett MJ; Broady RC; Connors JM; Forrest DL; Gerrie AS; Hogge DE; Narayanan S; Nevill TJ; Nantel SH; Power MM; Sutherland HJ; Villa D; Shepherd JD; Song KW
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):341-8. PubMed ID: 25656914
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Aggressive B-cell lymphomas of gastrointestinal tract: a clinicopathologic analysis of 54 cases].
    Zhou J; Xia C; Shen Q; Yin H; Zhang X; Shi Q; Zhou X; Ma J
    Zhonghua Bing Li Xue Za Zhi; 2014 Jan; 43(1):8-14. PubMed ID: 24713242
    [TBL] [Abstract][Full Text] [Related]  

  • 44. TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations.
    Gebauer N; Bernard V; Gebauer W; Thorns C; Feller AC; Merz H
    Leuk Lymphoma; 2015 Jan; 56(1):179-85. PubMed ID: 24679006
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The impact of MYC rearrangements and "double hit" abnormalities in diffuse large B-cell lymphoma.
    Lin P; Medeiros LJ
    Curr Hematol Malig Rep; 2013 Sep; 8(3):243-52. PubMed ID: 23892979
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diffuse swelling of the buccal mucosa and palate as first and only manifestation of an extranodal non-Hodgkin 'double-hit' lymphoma: report of a case.
    Frei M; Dubach P; Reichart PA; Schmitt AM; Mueller-Garamvölgyi E; Bornstein MM
    Oral Maxillofac Surg; 2012 Mar; 16(1):69-74. PubMed ID: 20981461
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment intensification might not improve survival in high-grade B-cell lymphoma with a concurrent MYC and BCL2 and/or BCL6 rearrangement: A retrospective, multicenter, pooled analysis.
    Zeremski V; McPhail ED; Habermann TM; Schieppati F; Gebauer N; Vassilakopoulos TP; Mougiakakos D
    Hematol Oncol; 2023 Oct; 41(4):776-780. PubMed ID: 36945194
    [No Abstract]   [Full Text] [Related]  

  • 48. Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival.
    Cohen JB; Geyer SM; Lozanski G; Zhao W; Heerema NA; Hall NC; Nagar VA; Hemminger JA; Jones JA; Porcu P; Christian BA; Baiocchi RA; Maddocks KJ; Flynn JM; Devine SM; Blum KA
    Cancer; 2014 Jun; 120(11):1677-85. PubMed ID: 24578014
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Simple karyotype and bcl-6 expression predict a diagnosis of Burkitt lymphoma and better survival in IG-MYC rearranged high-grade B-cell lymphomas.
    Seegmiller AC; Garcia R; Huang R; Maleki A; Karandikar NJ; Chen W
    Mod Pathol; 2010 Jul; 23(7):909-20. PubMed ID: 20348878
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
    Valera A; López-Guillermo A; Cardesa-Salzmann T; Climent F; González-Barca E; Mercadal S; Espinosa I; Novelli S; Briones J; Mate JL; Salamero O; Sancho JM; Arenillas L; Serrano S; Erill N; Martínez D; Castillo P; Rovira J; Martínez A; Campo E; Colomo L;
    Haematologica; 2013 Oct; 98(10):1554-62. PubMed ID: 23716551
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma.
    Fiskvik I; Beiske K; Delabie J; Yri O; Spetalen S; Karjalainen-Lindsberg ML; Leppä S; Liestøl K; Smeland EB; Holte H
    Leuk Lymphoma; 2015 Jun; 56(6):1742-9. PubMed ID: 25284491
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Double hit lymphoma: the MD Anderson Cancer Center clinical experience.
    Oki Y; Noorani M; Lin P; Davis RE; Neelapu SS; Ma L; Ahmed M; Rodriguez MA; Hagemeister FB; Fowler N; Wang M; Fanale MA; Nastoupil L; Samaniego F; Lee HJ; Dabaja BS; Pinnix CC; Medeiros LJ; Nieto Y; Khouri I; Kwak LW; Turturro F; Romaguera JE; Fayad LE; Westin JR
    Br J Haematol; 2014 Sep; 166(6):891-901. PubMed ID: 24943107
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Clinicopathologic Features and Molecular Signatures of Blastoid High-Grade B Cell Lymphoma, Not Otherwise Specified.
    Qiu L; Lin P; Khanlari M; Xu J; Cohen EN; Garces S; Miranda RN; Wang W; Fang H; Bueso-Ramos CE; Medeiros LJ; Li S
    Mod Pathol; 2023 Dec; 36(12):100349. PubMed ID: 37820764
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection?
    Nowakowski GS; Czuczman MS
    Am Soc Clin Oncol Educ Book; 2015; ():e449-57. PubMed ID: 25993209
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MYC alterations in diffuse large B-cell lymphomas.
    Karube K; Campo E
    Semin Hematol; 2015 Apr; 52(2):97-106. PubMed ID: 25805589
    [TBL] [Abstract][Full Text] [Related]  

  • 56. miR expression in MYC-negative DLBCL/BL with partial trisomy 11 is similar to classical Burkitt lymphoma and different from diffuse large B-cell lymphoma.
    Zajdel M; Rymkiewicz G; Chechlinska M; Blachnio K; Pienkowska-Grela B; Grygalewicz B; Goryca K; Cieslikowska M; Bystydzienski Z; Swoboda P; Walewski J; Siwicki JK
    Tumour Biol; 2015 Jul; 36(7):5377-88. PubMed ID: 25677902
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antigen expression patterns of MYC-rearranged versus non-MYC-rearranged B-cell lymphomas by flow cytometry.
    Mandelker DL; Dorfman DM; Li B; Pozdnyakova O
    Leuk Lymphoma; 2014 Nov; 55(11):2592-6. PubMed ID: 24397618
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma.
    Green MR; Vicente-Dueñas C; Romero-Camarero I; Long Liu C; Dai B; González-Herrero I; García-Ramírez I; Alonso-Escudero E; Iqbal J; Chan WC; Campos-Sanchez E; Orfao A; Pintado B; Flores T; Blanco O; Jiménez R; Martínez-Climent JA; Criado FJ; Cenador MB; Zhao S; Natkunam Y; Lossos IS; Majeti R; Melnick A; Cobaleda C; Alizadeh AA; Sánchez-García I
    Nat Commun; 2014 Jun; 5():3904. PubMed ID: 24887457
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An increase in
    Schieppati F; Balzarini P; Fisogni S; Re A; Pagani C; Bianchetti N; Micheli L; Passi A; Ferrari S; Maifredi A; Bottelli C; Leopaldo R; Pellegrini V; Facchetti F; Rossi G; Tucci A
    Haematologica; 2020 May; 105(5):1369-1378. PubMed ID: 31399522
    [No Abstract]   [Full Text] [Related]  

  • 60. Primary cardiac large B cell lymphoma.
    Arun Kumar S; Mishra R; Malempati SC; Bindal P
    BMJ Case Rep; 2023 Dec; 16(12):. PubMed ID: 38151268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.